# Ligand Pharmaceuticals Incorporated (LGND) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $285.60, market value $5.7 billion.

## Valuation
- **P/E (trailing): 29.4×** (5-yr avg 28.1×, 3-yr avg 27.6×). Ligand Pharmaceuticals Incorporated trades at 29.4× trailing earnings, close to its own five-year average of 28.1×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 23.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.01**. A PEG of 0.01 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 19.6×**. Each dollar of revenue is priced at 19.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.9×**. The shares trade at 5.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 43.4×**. Enterprise value is 43.4× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.3%** (5-yr avg 4.9%). Free cash flow equals 2.3% of the market value, below its five-year average of 4.9%, so the shares are pricier on cash than usual.
- **Earnings yield: 3.4%**. The inverse of the P/E: 3.4% of the price is earned each year.

## Profitability
- **Operating margin: 32.6%**. 32.6% of revenue is left after running the business, an exceptional level.
- **Net margin: 46.4%**. 46.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.2%**. 12.2% on shareholders' equity is solid.
- **Return on invested capital: 8.6%**. Return on all capital, debt included, is 8.6%.
- **Return on assets: 12.6%**. Each dollar of assets produces 12.6% of profit.

## Growth
- **Revenue growth (1 yr): 60.4%** (3-yr 11.0%/yr, 5-yr 10.4%/yr). Revenue grew 60.4% over the last year, against 10.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 2886.4%**. Earnings per share rose 2886.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -25.8%/yr**. Free cash flow has compounded at -25.8% a year over three years.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Ligand Pharmaceuticals Incorporated holds more cash than debt.
- **Current ratio: 22.23** (quick 22.23). Current assets cover the next year's liabilities 22.23 times.
- **Altman Z-score: 8.07**. A Z-score of 8.07 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Ligand Pharmaceuticals Incorporated does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 70.3%** (YTD 51.1%, 3-mo 20.5%). The shares are up 70.3% over twelve months including dividends.
- **From 52-week high: -12.6%** (76.5% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.86** (volatility 36%). Beta of 0.86 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LGND · Page: https://foliofundamentals.com/stocks/lgnd

Not investment advice.